Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2023 Sep;80(9):1834-1842.
doi: 10.1161/HYPERTENSIONAHA.122.20732. Epub 2023 Jun 1.

Intensive Blood Pressure Lowering Improves Left Ventricular Hypertrophy in Older Patients with Hypertension: The STEP Trial

Yue Deng #  1 , Wei Liu #  2 , Xinchun Yang #  3 , Zihong Guo #  4 , Juyan Zhang  5 , Rongjie Huang  6 , Xiaomin Yang  7 , Chunli Yu  8 , Jing Yu  9 , Jun Cai  1 ; STEP Study Group
Affiliations
Randomized Controlled Trial

Intensive Blood Pressure Lowering Improves Left Ventricular Hypertrophy in Older Patients with Hypertension: The STEP Trial

Yue Deng et al. Hypertension. 2023 Sep.

Erratum in

Abstract

Background: Intensive systolic blood pressure (SBP) lowering has been increasingly used; however, its effect on cardiac remodeling remains not fully understood. This secondary analysis of the Strategy of Blood Pressure Intervention in the Elderly Hypertensive Patients trial aims to determine the changes in left ventricular hypertrophy (LVH) that occur in the context of intensive SBP lowering.

Methods: A total of 7141 older patients with hypertension were randomly assigned to intensive treatment (SBP target, 110-130 mm Hg) or standard treatment (130-150 mm Hg). LVH was defined according to the Peguero-Lo Presti criteria on a standard 12-lead echocardiogram.

Results: At baseline, the prevalence of LVH (16.6% versus 16.5%) and the mean Peguero-Lo Presti value (1811 versus 1808 μV) were comparable between the treatment groups. During a median follow-up of 3.24 years, intensive SBP lowering was associated with a significantly lower risk of new LVH occurrence (hazard ratio, 0.76 [95% CI, 0.66-0.89]; P=0.001) and slower progression of the mean Peguero-Lo Presti index value by -23.47 μV/y (95% CI, -34.93 to -12.01; P=0.000). However, the rates of regression of baseline LVH did not differ significantly. Notably, the beneficial effect of intensive SBP lowering in terms of cardiovascular events (hazard ratio, 0.75 [95% CI, 0.59-0.97]) was not markedly attenuated after adjusting for LVH as a time-varying covariate (hazard ratio, 0.76 [95% CI, 0.59-0.97]).

Conclusions: Intensive SBP lowering protects against LVH development in older hypertensive patients, however, this favorable effect could not explain most of the reduction in cardiovascular events associated with intensive SBP lowering.

Keywords: blood pressure; cardiovascular disease; elderly; hypertrophy.

PubMed Disclaimer

Conflict of interest statement

Disclosures None.

Figures

Figure 1.
Figure 1.
Forest plot showing the results of the prespecified subgroup analysis of the effect of intensive treatment vs standard treatment on the risk of new left ventricular hypertrophy during follow-up. Results are presented as the hazard ratio (HR) and 95% CI. The dashed line represents the overall HR.
Figure 2.
Figure 2.
Forest plot showing the results of the prespecified subgroup analysis of the effect of intensive treatment vs standard treatment on the risk of regression of existing left ventricular hypertrophy (LVH) during follow-up. Results are presented as the hazard ratio (HR) and 95% CI. The dashed line represents the overall HR.
Figure 3.
Figure 3.
Forest plot of the progression of Pegeuro-Lo Presti value of intensive vs standard treatment throughout follow-up. Results are presented as the mean and 95% CI of between-group difference of the progression Pegeuro-Lo Presti value per year (µV).
See this image and copyright information in PMC

Comment in

References

    1. Yan Y, Li S, Guo Y, Fernandez C, Bazzano L, He J, Mi J, Chen W; International Childhood Cardiovascular Cohort Consortium Investigators. Life-course cumulative burden of body mass index and blood pressure on progression of left ventricular mass and geometry in midlife: the Bogalusa Heart Study. Circ Res. 2020;126:633–643. doi: 10.1161/CIRCRESAHA.119.316045 - PMC - PubMed
    1. Manyari DE. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med. 1990;323:1706–1707. doi: 10.1056/NEJM199012133232413 - PubMed
    1. Fagard RH, Celis H, Thijs L, Wouters S. Regression of left ventricular mass by antihypertensive treatment: a meta-analysis of randomized comparative studies. Hypertension. 2009;54:1084–1091. doi: 10.1161/HYPERTENSIONAHA.109.136655 - PubMed
    1. Mathew J, Sleight P, Lonn E, Johnstone D, Pogue J, Yi Q, Bosch J, Sussex B, Probstfield J, Yusuf S; Heart Outcomes Prevention Evaluation (HOPE) Investigators. Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril. Circulation. 2001;104:1615–1621. doi: 10.1161/hc3901.096700 - PubMed
    1. Okin PM, Devereux RB, Jern S, Kjeldsen SE, Julius S, Nieminen MS, Snapinn S, Harris KE, Aurup P, Edelman JM, et al. ; LIFE Study Investigators. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. JAMA. 2004;292:2343–2349. doi: 10.1001/jama.292.19.2343 - PubMed

Publication types

MeSH terms

Substances